-
公开(公告)号:US06919369B2
公开(公告)日:2005-07-19
申请号:US10224114
申请日:2002-08-19
申请人: Ignacio Aliagas-Martin , Dean R. Artis , Michael S. Dina , John A. Flygare , Richard A. Goldsmith , Regina A. Munroe , Alan G. Olivero , Richard Pastor , Thomas E. Rawson , Kirk D. Robarge , Daniel P. Sutherlin , Kenneth J. Weese , Aihe Zhou , Yan Zhu
发明人: Ignacio Aliagas-Martin , Dean R. Artis , Michael S. Dina , John A. Flygare , Richard A. Goldsmith , Regina A. Munroe , Alan G. Olivero , Richard Pastor , Thomas E. Rawson , Kirk D. Robarge , Daniel P. Sutherlin , Kenneth J. Weese , Aihe Zhou , Yan Zhu
IPC分类号: C07D333/34 , A61K31/18 , A61K31/196 , A61K31/216 , A61K31/381 , A61P7/02 , A61P9/10 , C07C257/18 , C07C311/05 , C07C311/08 , C07C311/13 , C07C311/18 , C07C311/29 , C07C311/51
CPC分类号: C07C257/18 , C07C311/05 , C07C311/08 , C07C311/13 , C07C311/18 , C07C311/29 , C07C311/51
摘要: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
摘要翻译: 具有如下结构的化合物可用于抑制丝氨酸蛋白酶,例如TF /因子VIIa,因子Xa,凝血酶和激肽释放酶。 这些化合物可用于预防和/或治疗凝血障碍的方法。
-
公开(公告)号:US06472393B1
公开(公告)日:2002-10-29
申请号:US09509104
申请日:2000-03-21
申请人: Ignacio Aliagas-Martin , Dean R. Artis , Michael S. Dina , John A. Flygare , Richard A. Goldsmith , Regina A. Munroe , Alan G. Olivero , Richard Pastor , Thomas E. Rawson , Kirk D. Robarge , Daniel P. Sutherlin , Kenneth J. Weese , Aihe Zhou , Yan Zhu
发明人: Ignacio Aliagas-Martin , Dean R. Artis , Michael S. Dina , John A. Flygare , Richard A. Goldsmith , Regina A. Munroe , Alan G. Olivero , Richard Pastor , Thomas E. Rawson , Kirk D. Robarge , Daniel P. Sutherlin , Kenneth J. Weese , Aihe Zhou , Yan Zhu
IPC分类号: A61K3118
CPC分类号: C07C257/18 , C07C311/05 , C07C311/08 , C07C311/13 , C07C311/18 , C07C311/29 , C07C311/51
摘要: Compounds having the structure shown below wherein A, B, N1, N2, X, Y, Q, R2, R5 and R6 are as defined herein are useful to inhibit serine protease enzymes, such as TF/factor VIIa factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
摘要翻译: 具有下述结构的化合物其中A,B,N1,N2,X,Y,Q,R2,R5和R6如本文所定义,可用于抑制丝氨酸蛋白酶,如TF /因子VIIa因子Xa,凝血酶和激肽释放酶 。 这些化合物可用于预防和/或治疗凝血障碍的方法。
-
公开(公告)号:US06706753B2
公开(公告)日:2004-03-16
申请号:US10313147
申请日:2002-12-06
申请人: Dean R. Artis , David Y. Jackson , Thomas E. Rawson , Mark E. Reynolds , Daniel P. Sutherlin , Mark S. Stanley
发明人: Dean R. Artis , David Y. Jackson , Thomas E. Rawson , Mark E. Reynolds , Daniel P. Sutherlin , Mark S. Stanley
IPC分类号: A61K314025
CPC分类号: C07D403/12 , C07C233/25 , C07C233/60 , C07C233/81 , C07C237/04 , C07C237/20 , C07C237/22 , C07C2601/08 , C07C2603/18 , C07C2603/32 , C07D207/16 , C07D207/48 , C07D209/88 , C07D405/12
摘要: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to &agr;4 integrin receptors and thereby inhibit binding of ligands for &agr;4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with &agr;4 integrins or their ligands.
摘要翻译: 提供式(I)的化合物,其中A,Q,W,X,Y,Z,R 1至R 4,m和n如本文所定义。 本发明的化合物结合α4整联蛋白受体,从而抑制用于α4整联蛋白的配体的结合,其可用于与α4整联蛋白或其配体相关的疾病和病症的预防和/或治疗性治疗。
-
公开(公告)号:US07265146B2
公开(公告)日:2007-09-04
申请号:US11111105
申请日:2005-04-20
申请人: Dean R. Artis , David Y. Jackson , Thomas E. Rawson , Mark E. Reynolds , Daniel P. Sutherlin , Mark S. Stanley
发明人: Dean R. Artis , David Y. Jackson , Thomas E. Rawson , Mark E. Reynolds , Daniel P. Sutherlin , Mark S. Stanley
IPC分类号: A61K31/403 , C07D207/04 , C07D209/82
CPC分类号: C07D403/12 , C07C233/25 , C07C233/60 , C07C233/81 , C07C237/04 , C07C237/20 , C07C237/22 , C07C2601/08 , C07C2603/18 , C07C2603/32 , C07D207/16 , C07D207/48 , C07D209/88 , C07D405/12
摘要: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to α4 integrin receptors and thereby inhibit binding of ligands for α4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with α4 integrins or their ligands.
摘要翻译: 提供式(I)的化合物,其中A,Q,W,X,Y,Z,R 1至R 4,m和n如本文所定义。 本发明的化合物结合α4H整联蛋白受体,从而抑制用于α4A整联蛋白的配体的结合,其可用于预防和/或治疗与 α4整联蛋白或其配体。
-
公开(公告)号:US06933314B2
公开(公告)日:2005-08-23
申请号:US10676706
申请日:2003-09-30
申请人: Dean R. Artis , David Y. Jackson , Thomas E. Rawson , Mark E. Reynolds , Daniel P. Sutherlin , Mark S. Stanley
发明人: Dean R. Artis , David Y. Jackson , Thomas E. Rawson , Mark E. Reynolds , Daniel P. Sutherlin , Mark S. Stanley
IPC分类号: A61K31/195 , A61K31/403 , A61P1/04 , A61P1/12 , A61P1/16 , A61P1/18 , A61P3/10 , A61P11/00 , A61P11/02 , A61P11/06 , A61P15/14 , A61P17/00 , A61P17/06 , A61P19/02 , A61P25/28 , A61P29/00 , A61P37/00 , A61P43/00 , C07C233/25 , C07C233/60 , C07C233/81 , C07C237/04 , C07C237/20 , C07C237/22 , C07C237/42 , C07D207/16 , C07D207/48 , C07D209/88 , C07D403/12 , C07D405/12 , C07D209/82
CPC分类号: C07D403/12 , C07C233/25 , C07C233/60 , C07C233/81 , C07C237/04 , C07C237/20 , C07C237/22 , C07C2601/08 , C07C2603/18 , C07C2603/32 , C07D207/16 , C07D207/48 , C07D209/88 , C07D405/12
摘要: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to α4 integrin receptors and thereby inhibit binding of ligands for α4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with α4 integrins or their ligands.
摘要翻译: 提供式(I)的化合物,其中A,Q,W,X,Y,Z,R 1至R 4,m和n如本文所定义。 本发明的化合物结合α4H整联蛋白受体,从而抑制用于α4A整联蛋白的配体的结合,其可用于预防和/或治疗与 α4整联蛋白或其配体。
-
公开(公告)号:US06410733B1
公开(公告)日:2002-06-25
申请号:US09947424
申请日:2001-09-05
IPC分类号: C07D21514
CPC分类号: C07D401/06 , C07D207/16 , C07D207/48 , C07D401/12 , C07D403/12
摘要: Inhibitors of serine proteases are provided having formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein. In particular, the compounds bind to factor VIIa, tissue factor/factor Xa complex, thrombin, trypsin, plasmin and kallikrein and have anticoagulant activity. Pharmaceutical compositions comprising the compounds are useful for inhibiting the formation of veinous and/or arterial thrombi in vivo.
摘要翻译: 提供丝氨酸蛋白酶的抑制剂,其具有式(I),其中X,R 1,R 2,R 3,R 4和R 5如本文所定义。 特别地,化合物结合因子VIIa,组织因子/因子Xa复合物,凝血酶,胰蛋白酶,纤溶酶和激肽释放酶,并具有抗凝活性。 包含该化合物的药物组合物可用于在体内抑制静脉和/或动脉血栓的形成。
-
公开(公告)号:US06838479B2
公开(公告)日:2005-01-04
申请号:US10363557
申请日:2001-09-05
申请人: Richard M Pastor , Dean R. Artis , Alan G. Olivero
发明人: Richard M Pastor , Dean R. Artis , Alan G. Olivero
IPC分类号: A61K31/401 , A61K31/404 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61P7/02 , A61P43/00 , C07D207/16 , C07D207/48 , C07D401/06 , C07D401/12 , C07D403/12 , A61K31/40 , C07D207/12
CPC分类号: C07D401/06 , C07D207/16 , C07D207/48 , C07D401/12 , C07D403/12
摘要: Inhibitors of serine proteases are provided having formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein. In particular, the compounds bind to factor VIIa, tissue factor/factor Xa complex, thrombin, trypsin, plasmin and kallikrein and have anticoagulant activity. Pharmaceutical compositions comprising the compounds are useful for inhibiting the formation of veinous and/or arterial thrombi in vivo.
摘要翻译: 提供丝氨酸蛋白酶的抑制剂,其具有式(I),其中X,R 1,R 2,R 3,R 4和R 5如本文所定义。 特别地,化合物结合因子VIIa,组织因子/因子Xa复合物,凝血酶,胰蛋白酶,纤溶酶和激肽释放酶,并具有抗凝活性。 包含该化合物的药物组合物可用于在体内抑制静脉和/或动脉血栓的形成。
-
8.
公开(公告)号:US20150087826A1
公开(公告)日:2015-03-26
申请号:US14556914
申请日:2014-12-01
申请人: Ying-Zi Xu , Dean R. Artis , Simeon Bowers , Roy K. Hom , Hing L. Sham , Shendong Yuan
发明人: Ying-Zi Xu , Dean R. Artis , Simeon Bowers , Roy K. Hom , Hing L. Sham , Shendong Yuan
IPC分类号: C07D513/10
CPC分类号: C07D513/10 , C07D265/12 , C07D265/18 , C07D279/08 , C07D279/16 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D498/10
摘要: Compounds are provided having a structure according to Formula (I): wherein A1, A2, A3, Y, R1, R2, R3, R4, R5, R6, m, n and p are defined herein. Further provided are pharmaceutical compositions including the compounds provided and methods of making and using the compounds and compositions as provided, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
-
9.
公开(公告)号:US08470818B2
公开(公告)日:2013-06-25
申请号:US12906980
申请日:2010-10-18
申请人: Prabha N. Ibrahim , Dean R. Artis , Ryan Bremer , Shumeye Mamo , Chao Zhang , Jiazhong Zhang , Jianming Tsai , Klaus-Peter Hirth , Gideon Bollag , Wayne Spevak , Hanna Cho , Samuel J. Gillette , Shenghua Shi
发明人: Prabha N. Ibrahim , Dean R. Artis , Ryan Bremer , Shumeye Mamo , Chao Zhang , Jiazhong Zhang , Jianming Tsai , Klaus-Peter Hirth , Gideon Bollag , Wayne Spevak , Hanna Cho , Samuel J. Gillette , Shenghua Shi
IPC分类号: A61K31/535
CPC分类号: C07D471/04 , A61K31/437 , A61K31/496 , A61K31/5377 , C07C37/62 , C07C39/27 , C07C45/00 , C07C45/673 , C07C45/71 , C07C47/565 , C07C47/575 , C07D209/08
摘要: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
摘要翻译: 描述了对蛋白激酶有活性的化合物,以及使用这些化合物治疗与蛋白激酶异常活性相关的疾病和病症的方法。
-
公开(公告)号:US08415469B2
公开(公告)日:2013-04-09
申请号:US12616079
申请日:2009-11-10
申请人: Prabha N. Ibrahim , Dean R. Artis , Ryan Bremer , Gaston Habets , Shumeye Mamo , Marika Nespi , Chao Zhang , Jiazhong Zhang , Yong-Liang Zhu , Rebecca Zuckerman , Brian West , Yoshisa Suzuki , Jianming Tsai , Klaus-Peter Hirth , Gideon Bollag , Wayne Spevak , Hanna Cho , Samuel J. Gillette , Guoxian Wu , Hongyao Zhu , Shenghua Shi
发明人: Prabha N. Ibrahim , Dean R. Artis , Ryan Bremer , Gaston Habets , Shumeye Mamo , Marika Nespi , Chao Zhang , Jiazhong Zhang , Yong-Liang Zhu , Rebecca Zuckerman , Brian West , Yoshisa Suzuki , Jianming Tsai , Klaus-Peter Hirth , Gideon Bollag , Wayne Spevak , Hanna Cho , Samuel J. Gillette , Guoxian Wu , Hongyao Zhu , Shenghua Shi
IPC分类号: C07D413/14 , C07D401/14 , C07D471/04 , C07F7/02
CPC分类号: C07D471/04 , A61K31/437 , A61K31/496 , A61K31/5377 , C07C37/62 , C07C39/27 , C07C45/00 , C07C45/673 , C07C45/71 , C07C47/565 , C07C47/575 , C07D209/08
摘要: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
-
-
-
-
-
-
-
-
-